Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
ERBB-mutaties als biomarker voor uitkomst plaveiselcelcarcinoom van de long?
jan 2019 | Longoncologie